Difference between revisions of "Chidamide (Epidaza)"
Jump to navigation
Jump to search
m (→Also known as) |
Warner-admin (talk | contribs) m (Text replacement - "Category:Drug index" to "Category:Drugs") |
||
| Line 13: | Line 13: | ||
*'''Brand name:''' Epidaza | *'''Brand name:''' Epidaza | ||
| − | [[Category: | + | [[Category:Drugs]] |
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
[[Category:HDAC inhibitors]] | [[Category:HDAC inhibitors]] | ||
Revision as of 22:12, 13 June 2018
Mechanism of action
HDAC inhibitor
Preliminary data
Peripheral T-cell lymphoma
- Shi Y, Dong M, Hong X, Zhang W, Feng J, Zhu J, Yu L, Ke X, Huang H, Shen Z, Fan Y, Li W, Zhao X, Qi J, Huang H, Zhou D, Ning Z, Lu X. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol. 2015 Aug;26(8):1766-71. Epub 2015 Jun 23. link to original article PubMed
History of changes in FDA indication
Not FDA approved, but is approved for use in China.
Also known as
- Code name: HBI-8000
- Brand name: Epidaza